Causes of Thrombocytopenia and Rash
When a patient presents with concurrent thrombocytopenia and rash, immediately consider vaccine-induced immune thrombocytopenia and thrombosis (VITT), thrombotic thrombocytopenic purpura (TTP), immune thrombocytopenic purpura (ITP), drug reactions (particularly heparin), and primary immunodeficiencies like Wiskott-Aldrich syndrome.
Critical Time-Sensitive Causes
Vaccine-Induced Immune Thrombocytopenia and Thrombosis (VITT)
VITT is a life-threatening emergency that occurs 5-30 days after COVID-19 vaccination 1. Key features include:
- Anti-platelet factor 4 (PF4) antibodies causing intense platelet and coagulation activation
- Symptoms: new unexplained pinprick bruising or bleeding, severe headaches, shortness of breath, leg swelling, persistent abdominal pain
- Thrombosis affects cerebral veins in 50% of cases; one-third have multiple-site thrombosis
- Immediate management: Start non-heparin anticoagulants and intravenous immunoglobulin as soon as possible 1
- Incidence: 14.9 per million after first dose, 1.8 per million after second dose, with twice the rate in adults 18-49 years versus ≥50 years
Thrombotic Thrombocytopenic Purpura (TTP)
TTP requires immediate plasma exchange to prevent mortality 2. This thrombotic microangiopathy presents with:
- ADAMTS13 activity measurement is the diagnostic gold standard 2
- Classic pentad (often incomplete): thrombocytopenia, microangiopathic hemolytic anemia, neurological abnormalities, renal dysfunction, fever
- Petechial rash can be the sole presenting manifestation 3
- Treatment protocol: Plasma exchange + corticosteroids + caplacizumab immediately upon clinical suspicion 2
- Mortality reduction: From 15.7% to 3.9% with plasma exchange; further reduced to 2.2% with standard treatment including rituximab 2
Drug-Induced Causes
Heparin-Induced Thrombocytopenia (HIT)
Heparin causes both skin lesions and thrombocytopenia 4:
- Delayed-type hypersensitivity reactions at injection sites are common
- Critical distinction: HIT skin lesions versus simple hypersensitivity
- Use the Warkentin 4T's score: If ≥4, perform skin biopsy and HIT laboratory testing immediately
- Management: Replace heparin with alternative anticoagulants (fondaparinux) as precautionary measure 4
- Obtain complete blood count immediately when skin lesions appear
Antibiotic Reactions
Aminopenicillins cause delayed-onset maculopapular drug eruptions in <7% of patients 5, though thrombocytopenia is not a typical feature unless part of a severe systemic reaction.
Immune-Mediated Causes
Immune Thrombocytopenic Purpura (ITP)
ITP presents with isolated thrombocytopenia and petechial rash 6:
- Typical manifestations: Mucocutaneous petechiae, gum bleeding, epistaxis, spontaneous ecchymosis
- Atypical presentations include widespread distribution over ocular and oral areas 6
- Treatment escalation: Conservative management → corticosteroids → intravenous immunoglobulin 6
- In tuberculosis-endemic areas, consider TB-associated ITP 7: Platelet count improves with anti-tuberculosis treatment plus prednisolone
Dermatomyositis-Associated TTP
Rare association where characteristic dermatomyositis skin findings coexist with underlying TTP 8. Investigate for TTP when dermatomyositis patients develop thrombocytopenia.
Primary Immunodeficiency
Wiskott-Aldrich Syndrome (WAS)
In boys with the triad of eczema, bleeding manifestations, and microthrombocytopenia, consider WAS 9:
- X-linked disorder with microthrombocytopenia, eczematous dermatitis, immune dysfunction
- Diagnostic clue: Recurrent or unusually severe bacterial skin and soft-tissue infections
- Laboratory findings: Severe microthrombocytopenia, elevated IgE with low IgM, T- and B-cell lymphopenia
- Confirmed by genetic testing (WAS variant)
- Management: Surgical drainage of infections, blood products, antibiotics, antimicrobial prophylaxis 9
Diagnostic Algorithm
- Obtain timing: Symptom onset relative to vaccinations (5-30 days suggests VITT), medication exposure, or infections
- Assess severity markers: Headache quality, neurological symptoms, thrombosis signs, bleeding extent
- Immediate laboratory testing:
- Complete blood count with peripheral smear
- ADAMTS13 activity for TTP
- Anti-PF4 antibodies if VITT suspected
- Coagulation profile
- Age and sex considerations: Young males with eczema suggest WAS; adults 18-49 years post-vaccination suggest VITT
- Geographic context: TB-endemic areas warrant TB workup with thrombocytopenia
Critical Pitfalls
- Do not delay plasma exchange while awaiting ADAMTS13 results if TTP is clinically suspected 2
- Do not use heparin-based anticoagulants in VITT—use non-heparin alternatives immediately 1
- Do not dismiss petechial rash as the sole manifestation—it can represent life-threatening TTP 3
- Do not overlook infection triggers: Concurrent viral infections or TB can cause or unmask thrombocytopenia with rash 9, 7